021-5137-0935
sales@aqbiopharma.com.cn
Aqbiopharma was founded in 2007 as one of China’s early enterprises specializing in the dedicated R&D of fluorinated new drugs and fluorinated pharmaceutical intermediates.
The company operates a 2,800 m² R&D and pilot testing center and a 51 mu industrial production base. After nearly 20 years of continuous investment and technological research, we have developed more than 3,000 mass-producible products. Multiple core process technologies and new drug research achievements have been filed for invention patents, with a total of 30 patents granted.
Our main products cover a full range of fluorinated pharmaceutical intermediates, including heterocyclic fluorine building blocks such as piperidine, piperazine, pyrrolidine, azaindole, adamantane, aza-spirocycles and aza-fused rings.[View details]
Congratulations on the successful project of "Shanghai Green Fluoropharmaceutical Engineering Technology Research Center" jointly established by Aqikang Medical Science and Technology and Shanghai University of Applied Technology!
Nucleic acid drugs are drugs that use the translation or regulation function of nucleic acid molecules to intervene in diseases. Compared with traditional small molecule drugs and antibody drugs, nucleic acid drugs can intervene at the source, inhibit the expression of disease-related genes into pathological proteins, or introduce genes that can express normal proteins.
No content！
